Thiol-mediated apoptosis in prostate carcinoma cells

Cancer

Volumn 88, Issue 9, 2000, Pages 2092-2104

  Coffey, Ronan N T ^a   Watson, R William G ^a   Hegarty, Nicholas J ^a   O'Neill, Amanda ^a   Gibbons, Norma ^a   Brady, Hugh R ^a   Fitzpatrick, John M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Bcl 2; Caspases; Glutathione; Mitochondria; Prostate carcinoma

Indexed keywords

CASPASE; PROTEIN BCL 2; THIOL DERIVATIVE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR LOCALIZATION;

ANNEXIN A5; ANTI-BACTERIAL AGENTS; APOPTOSIS; BCL-X PROTEIN; BONGKREKIC ACID; CARCINOMA; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; COLORING AGENTS; DIAMIDE; DNA, NEOPLASM; ENZYME INHIBITORS; ENZYME PRECURSORS; GLUTATHIONE; HUMANS; MALE; MALEATES; MITOCHONDRIA; OXIDATION-REDUCTION; PROPIDIUM; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; SULFHYDRYL REAGENTS; TUMOR CELLS, CULTURED;

EID: 0034193205     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9     Document Type: Article

References (45)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. Cancer J Clin 1998;45:8-30.
2. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 1994;5: 391-400.
3. Denmeade SR, Lin, XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate. Prostate 1996;28:251-65.
4. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997;32:284-93.
5. Denmeade SR, Isaacs JT. Prostate cancer: where are we and where are we going? CA Cancer J Clin 1997;79:2-7.
6. Watson RWG, Rotstein OD, Avery B, Nathens A, Dackiw PB, Marshall J C. Thiol-mediated redox regulation of neutrophil apoptosis. Surgery 1996;120:150-8.
7. Diels J, Dobbelsteen C, Stefan I, Nobel J, Schlegel A, Cotgreave O, et al. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/apo-1 antibody. J Biol Chem 1996;271:15420-7.
8. Voehringer DW, Mc Conkey DJ, McDonnell TJ, Brisbay S, Mezõ I. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci U S A 1998;95:2956-60.
9. Buttke TM, Sandstrom P. Oxidative stress as a mediator of apoptosis. Immunol Today 1997;15:7-10.
10. Hug H, Enari M, Nagata S. No requirement of reactive oxygen intermediates in Fas-mediated apoptosis. FEBS Lett 1994;351:311-3.
11. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
12. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kägi D, et al.Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998;12:806-19.
13. Pascal V, Scott H, Earnshaw CW. Caspases and caspase inhibitors. TIBS 1997;22:388-93.
14. Lucio G, Sheldon BJ. Effect of diethylmaleate and other glutathione depletors on protein synthesis. Biochem Pharmocol 1986;35:3383-9.
15. Thatte U, Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs 1997;54:511-32.
16. Denmeade RS, Isaacs TJ. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 1999;35:281-306.
17. Fernandez A, Kiefer J, Fosdick L, McConkey J. Oxygen radical production and thiol depletion are required for calcium-mediated endogenous endonuclease activation in apoptotic thymocytes. J Immunol 1995;155:5133-9.
18. Andrezez W, Gasdaska JR, Powis G, Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 1996;4:735-51.
19. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:44-51.
20. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirch T, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1999;182: 367-77.
21. Marchetti P, Castedo M, Susin A, Naoufal Z, Hirch T, Macho A, et al. Mitochondrial permeability transition is a central coordinating event in apoptosis. J Exp Med 1996;184:1155-60.
22. Marchetti P, Decaudin D, Macho A, Zamzami N, Hirsch T, Susin SA, Kroemer G. Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Eur J Immunol 1997;27:289-96.
23. Kroemer G. The mitochondrion as an integrator and coordinator of cell death pathways. Cell Death Diff 1998;5: 547.
24. Solary E, Eymin B, Droin N, Haugg M. Proteases, proteolysis, and apoptosis. Cell Biol Toxicol 1998;14:121-32.
25. Green D, Kraemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 1998;8:267-71.
26. Mancini M, Nicholson DW, Roy S, Thornberry NA, Peterson EP, Casciola RL, et al. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signalling. J Cell Biol 1998;140:1485-95.
27. Krajewska M, Wang HG, Krajewski S, Zapata JM, Shabaik A, Gascoyne R, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 1997;57:1605-13.
28. Srikanth S, Kraft AS. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 1998;58:834-9.
29. Marcelli M, Cunningham GR, Walkup M, Sturgis L, Kagan C, Mannucci R, et al. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999;59:382-90.
30. Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Doussis Al, Biddolph S, et al. Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 1996;179:10-4.
31. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
32. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Partial 1994;145:1323-36.
33. Bonnette B, Favre N, Moutet M, Fromentin A, Solary E, Martin M, et al. Bcl-2 mediated inhibition of apoptosis prevents immunogeneicity and restores tumourigenicity of spontaneously regressive tumors. J Immunol 1998;161: 1433-8.
34. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1988;34:251-8.
35. Kyprianou N, King ED, Bradbury D, Rhee JG. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-8.
36. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
37. 1 interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A 1998;95: 4386-91.
38. Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 1998;95:554-9.
39. Canada A, Herman L, Kidd K, Robertson C, Trump D. Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line. Cancer Chemother Pharmacol 1993;32:73-7.
40. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, Mc-Donnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 1997;15:1461-70.
41. Jordan J, d'Arcy Doherty M, Cohen GM. Effects of glutathione depletion on the cytoxicity of agents toward a human colonic tumour cell line. Br J Cancer 1987;55:627-31.
42. Kauvar LM, Morgan AS, Sanderson PE, Henner WD. Glutathione-based approaches to improving cancer treatment. Chem Biol Interact 1998;111-112:225-38.
43. Chen X, Carystinos GD, Batist G. Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 1998;111-112:263-75.
44. Bhanumathi P, Devi PU. Modulation of glutathione depletion and lipid peroxidation by WR-77913 an 2-mercaptoporpionylglycine in cyclophosphamide chemotherapy. Indian J Exp Biol 1994;32:562-4.
45. Estrela JM, Obrador E, Navarro J, Lasso MC, Pellicer JA. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat Med 1995;1: 84-8.